Evotec could receive up to $41 million in research fees from the Huntington’s disease organization CHDI Foundation as part of an extension to an ongoing research collaboration through to the end of 2015. Through the partnership Evotec is providing the full breadth of its drug discovery platform, expertise in neurological research, and associated capabilities in medicinal chemistry, in vitro and in vivo pharmacology, and compound management.
CHDI says the partnership with Evotec, which has been ongoing since 2006, is one of its largest and longest-standing relationships with a CRO. “We are delighted that CHDI, an organization dedicated solely to the quest to discover novel drugs against Huntington’s disease, continues to work in partnership with Evotec,” states Mario Polywka, Ph.D., Evotec COO. “This collaboration is an excellent example of how companies, including foundations such as CHDI, can access Evotec’s platform suite of technologies, capabilities, and strong disease biology expertise to drive their drug discovery efforts.”
Evotec offers both stand-alone and fully integrated drug discovery services, and has established drug discovery partnerships with biotech and pharma firms including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen, MedImmune/AstraZeneca, and Ono Pharmaceuticals. The firm also has ongoing drug development partnerships in place with Boehringer Ingelheim, MedImmune, Andromeda in the field of diabetes, and with Roche in the field of Alzheimer’s disease. Within the last few weeks Evotec received preclinical milestone payments relating to its a ongoing drug discovery collaborations with Novartis, and with Boehringer Ingelheim. At the start of October Evotec and Bayer entered into a five-year, multi-target collaboration that aims to develop three clinical candidates for the treatment of endometriosis.